Provenge (sipuleucel-T) is an autologous cellular immunotherapy, which involves removing immune cells from a patient's blood, priming them to recognise prostate cancer, and then returning them to ...

In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration ...

The two trials randomized patients 2:1 to receive either sipuleucel-T immunotherapy—autologous peripheral blood mononuclear cells loaded with a recombinant fusion protein comprising prostatic ...

Objective: To review the activity of 3 new agents approved for the management of advanced castration-resistant prostate cancer (CRPC): sipuleucel-T, cabazitaxel, and abiraterone acetate.

It’s been 13 years since the FDA approved its first therapeutic vaccine – Dendreon Pharma’s Provenge (sipuleucel-T) for prostate cancer, which was not a commercial success – and since then ...

This vaccine, called sipuleucel-T (brand name Provenge), helps direct the immune system to attack a typically incurable form of prostate cancer. The vaccine contains a patient's own cells ...